Cytyc Has About $180 Mil. To Invest Following Collapse Of Digene Merger
This article was originally published in The Gray Sheet
Executive Summary
Cytyc could leverage a strong cash position to expand its core women's health diagnostic business in the wake of a scuttled merger with Digene
You may also be interested in...
Digene Will Achieve Strategic Goals Faster Through Qiagen Merger, CEO Says
Human papillomavirus test maker Digene will expand its international presence and gain critical mass to help counter looming competition in the lucrative HPV test market by merging with Dutch molecular diagnostics firm Qiagen
Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations
Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations